EUVIMEDEUVIMED entdecken
Open Access

QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation

Samantha R Giffen, Jacob M Sadler, Melissa B Miller iD

Journal of Clinical Microbiology · 2023

DOI: 10.1128/jcm.00859-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2023. Verfasst von Samantha R Giffen und 2 weiteren Autor:innen. Beteiligte Einrichtung: McLendon Clinical Microbiology Laboratories, University of North Carolina Medical Center , Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Cryptosporidiosis, Cryptosporidium, Gastroenteritis, Rotavirus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The diagnosis of acute gastroenteritis is an ongoing clinical challenge in terms of identification of the etiologic agent, time to results, and appropriate treatment. Rapid detection of gastrointestinal pathogens is needed to improve patient care. This study evaluates the performance of the QIAstat-Dx gastrointestinal panel (Q-GP; Investigational Use Only) compared to the Luminex xTAG gastrointestinal pathogen panel (L-GPP; US-IVD). Using 245 stool specimens, we evaluated 10 different targets including rotavirus, norovirus, Salmonella , Shigella , Campylobacter , Giardia , Cryptosporidium , Escherichia coli O157, enterotoxigenic E. coli (ETEC), and Shiga toxin-producing E. coli (STEC). For the viral targets, the percent positive agreement (PPA) for rotavirus was 100% ( n = 19) and that for norovirus was 91% (20/22). For the parasitic targets, the PPA was 100% for Giardia and Cryptosporidium ( n = 18 and n = 23, respectively). The PPA was 96% for Salmonella (22/23) and Campylobacter (22/23), and the PPA for Shigella was 100% ( n = 23). For the E. coli targets, a PPA of 94% was achieved for STEC (32/34) and 96% for ETEC (24/25). We did not assess PPA for the E. coli O157 target as the Q-GP O157 call is stx dependent. The negative percent agreement across all targets was 99.1%. Our study suggests that QIAstat-Dx GP provides comparable results to Luminex GPP based on the analysis of targets found on both panels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryptosporidiosisCryptosporidiumGastroenteritisRotavirusNorovirusEscherichia coli O157CampylobacterHumansFeces

Stichwörter der Autor:innen

GI panelmultiplexsyndromic test

Autor:innen und Institutionen

  • McLendon Clinical Microbiology Laboratories, University of North Carolina Medical Center , Chapel Hill, North Carolina, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina Chapel Hill School of Medicine , Chapel Hill, North Carolina, USA.

ORCID-Profile: Melissa B Miller

Zitieren

APA

Giffen, S. R., Sadler, J. M., & Miller, M. B. (2023). QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00859-23

Vancouver

Giffen SR, Sadler JM, Miller MB. QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation. Journal of Clinical Microbiology. 2023. doi:10.1128/jcm.00859-23

BibTeX
@article{Giffen2023,
  author = {Giffen, Samantha R and Sadler, Jacob M and Miller, Melissa B},
  title = {QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation},
  journal = {Journal of Clinical Microbiology},
  year = {2023},
  doi = {10.1128/jcm.00859-23}
}
Kostenlos starten →